Skip to main content
Premium Trial:

Request an Annual Quote

Luminex, Tecan Co-developing Newborn Screening Platform

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex and the Tecan Group today announced a collaboration to develop new automated screening platform for the faster detection of potential health risks in newborns.

The global original equipment manufacturing agreement will combine Luminex's xMAP technology and LX200 instrument with Tecan's Freedom EVO liquid handling platform and HydroFlex Washer.

Terms of the deal were not announced.

In a joint statement, Luminex said that it expects to launch the platform, to be called NeoPlex4, in 2011 and "once it receives regulatory clearance, [it] will be a fully automated, walk-away testing platform for multiplexed newborn screening." The platform, it added, will increase laboratory efficiency, save "vital resources," and allow researchers to analyze more samples more quickly.

NeoPlex4 will test newborn infants for several different biomarkers linked to critical diseases. The firms did not identify the diseases but said that they can cause "severe" mental and physical disability if untreated. "Multiplexing these test together from one sample offers significant improvements in testing efficiency," they said.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.